Register Login

PMV Pharmaceuticals Inc (PMVP)

  • Event
  • June 08, 2022, 10:07 UTC

(75% Positive) PMV Pharmaceuticals, Inc. (PMVP) Announces Enrollment Update for achieved Due to Pandemic-Related Challenges, Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 5:04 a.m.

    📋 PMV Pharmaceuticals, Inc. (PMVP) - Clinical Trial Update

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 06:07:05

    Event Type: Clinical Trial Update

    Event Details:

    PMV Pharmaceuticals Inc (PMVP) Announces Clinical Trial Update PMV Pharmaceuticals Inc (PMVP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: achieved, mutation
    • Diseases/Conditions: higher dose cohorts per RECIST v1, solid tumors
    • Clinical Stage: Phase 1
    • Collaboration: RECIST
      • targeting p53, today announced that preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC1458
      • targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: PMV Pharmaceuticals Inc
    • CIK: 0001699382
    • Ticker Symbol: PMVP
    • Period End Date: 2022-06-07
    • Document Type: 8-K

Search

News categories